Alzamend Neuro (ALZN) Stock Price, News & Analysis

Company Overview

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $1.64 to $1.72
• 50-Day Range: $1.12 to $1.67
• 52-Week Range: $0.84 to $2.68
• Volume: 242,119 shs
• Average Volume: 106,194 shs
• Market Capitalization: $8.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Hold

Alzamend Neuro Stock Analysis - MarketRank™

Alzamend Neuro scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Alzamend Neuro has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Alzamend Neuro has a consensus price target of $28.00, representing about 1,586.7% upside from its current price of $1.66.

Amount of Analyst Coverage

Alzamend Neuro has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alzamend Neuro are expected to grow in the coming year, from ($1.05) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alzamend Neuro is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alzamend Neuro is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alzamend Neuro has a P/B Ratio of 8.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.74% of the float of Alzamend Neuro has been sold short.

Short Interest Ratio / Days to Cover

Alzamend Neuro has a short interest ratio ("days to cover") of 3.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alzamend Neuro has recently decreased by 25.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alzamend Neuro does not currently pay a dividend.

Dividend Growth

Alzamend Neuro does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.86

News Sentiment

Alzamend Neuro has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Alzamend Neuro this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ALZN on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alzamend Neuro insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.39% of the stock of Alzamend Neuro is held by insiders.

Percentage Held by Institutions

49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/22/2026
• Today: 8/30/2026
• Next Earnings (Estimated): 9/09/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALZN
• CIK: 1677077
• Web: www.alzamend.com
• Phone: 844-722-6303
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alzamend Neuro: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: +1,586.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -277.74%
• Return on Assets: -200.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.31
• Quick Ratio: 1.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 8.74

Miscellaneous

• Outstanding Shares: 4,830,000
• Free Float: 4,759,000
• Market Cap: $8.02 million
• Optionable: No Data
• Beta: 0.16